Biocon Of India In Talks With Bristol, Sanofi To Market Insulin Drug
This article was originally published in PharmAsia News
Executive Summary
India's Biocon is reported dealing with two major global suitors, U.S.-based Bristol-Myers Squibb and France's Sanofi to market Biocon's insulin drug